Semaglutide and Atrial Fibrillation A subanalysis of data from the STEP-HFpEF and STEP-HFpEF DM trials 5 showed that patients with aFib—45% of the STEP-HFpEF program population—have ...
ACC 2024 Semaglutide Benefits in HFpEFStep Beyond Weight Loss Drs Piña and Kosiborod discuss semaglutide in obesity-related HF with and without diabetes. Both STEPHFpEF trials show similar ...
After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...